Gemcitabine

目录号:S1714 别名: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine是核酸合成抑制剂,是有效、特异的脱氧胞苷类似物,用于化疗。

规格 价格 库存 购买数量  
RMB 1057.63 现货
RMB 782.86 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Gemcitabine是核酸合成抑制剂,是有效、特异的脱氧胞苷类似物,用于化疗。
体外研究

在CCRF-CEM人白血病细胞培养物中,Gemcitabine抑制50%的细胞生长,IC50为1 纳克/毫升。Gemcitabine和deoxycytidine联用使生物活性降低1000倍。[1] 在人胰腺癌L3.6pl细胞中,Gemcitabine和C225联用产生额外的细胞毒作用,并随Gemcitabine浓度增多而增强。[2] 在野生型A2780和耐顺铂ADDP细胞中,Gemcitabine和Cisplatin联用产生协同效应。 [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMECwOFU5KG6P MV\TRW5ITVJ?
ES4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHtTWM2OD1yLkCwNFY2OyCwTR?= MkLWV2FPT0WU
ACHN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jVcGlEPTB;MD6wNFA5QDdibl2= MVzTRW5ITVJ?
KYSE-510 M4\MS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISzcIJKSzVyPUCuNFAxQTd3IH7N NHPGeYZUSU6JRWK=
EW-7 NF3CSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XHU2lEPTB;MD6wNFI2QCCwTR?= M3X0XXNCVkeHUh?=
BFTC-905 NFzKWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEC1NVUhdk1? M{\KdXNCVkeHUh?=
KE-37 NEDTOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP1UYNKSzVyPUCuNFA2PjFibl2= MoLMV2FPT0WU
SBC-5 NYLPbndJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvvfolKSzVyPUCuNFA2PyCwTR?= MlXDV2FPT0WU
NKM-1 M3Tpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;aR2NsUUN3ME2wMlAxPzB7IH7N NWjM[JBmW0GQR1XS
RH-1 NFLjNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DKNGlEPTB;MD6wNFcyQCCwTR?= M{T2bnNCVkeHUh?=
ALL-PO M3vwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTuSGdKSzVyPUCuNFA5OyCwTR?= NHvrfnRUSU6JRWK=
QIMR-WIL MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LMdmlEPTB;MD6wNFg6PCCwTR?= NF;LVGdUSU6JRWK=
A375 M1HENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrGdZpKSzVyPUCuNFA6QTVibl2= NH;ldG1USU6JRWK=
SIG-M5 M1;6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXGTWM2OD1yLkCxNFQhdk1? MmDIV2FPT0WU
KGN NGXwT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrsZ|VZUUN3ME2wMlAyODhibl2= MVrTRW5ITVJ?
EW-13 NHnIfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XjNmlEPTB;MD6wNVEzKG6P MUjTRW5ITVJ?
NCI-SNU-1 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7vZ4dKSzVyPUCuNFE3KG6P MlXSV2FPT0WU
PSN1 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjNe|lKSzVyPUCuNFE3PSCwTR?= NFPXcnVUSU6JRWK=
HUTU-80 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXzbGJKSzVyPUCuNFE3PiCwTR?= M2Lx[HNCVkeHUh?=
EW-16 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vtSmlEPTB;MD6wNlMhdk1? MlP6V2FPT0WU
786-0 NI\RR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEKzJI5O NHrudIJUSU6JRWK=
ES1 NUHrR3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy3NJZKSzVyPUCuNFI3QCCwTR?= NIj4VXFUSU6JRWK=
RKO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEK3PUBvVQ>? NIOwNopUSU6JRWK=
ESS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrrcZFpUUN3ME2wMlAzQDZibl2= NFPZNlVUSU6JRWK=
SK-UT-1 M1\zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD1yLkCyPVchdk1? MXzTRW5ITVJ?
LB2241-RCC M{LPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLyNJZKSzVyPUCuNFMyQCCwTR?= M2Xp[XNCVkeHUh?=
CHL-1 NYLhc|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r6R2lEPTB;MD6wN|I1KG6P MV\TRW5ITVJ?
SW1783 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD1yLkCzN|Yhdk1? MXrTRW5ITVJ?
MEL-JUSO NEO0[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\vR4tkUUN3ME2wMlA{QTFibl2= Mn[5V2FPT0WU
HT-29 M2nuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzERVdKSzVyPUCuNFQyOyCwTR?= MlXSV2FPT0WU
SNG-M NWnDO2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPPTWM2OD1yLkC0NlUhdk1? MoC0V2FPT0WU
TE-15 NVq0WnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPO[3FKSzVyPUCuNFQ3PCCwTR?= MXvTRW5ITVJ?
HOS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMES4JI5O NHGxOJRUSU6JRWK=
BB65-RCC NVzjd5BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDacFl4UUN3ME2wMlA2OTJibl2= MmixV2FPT0WU
HCE-4 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PhVmlEPTB;MD6wOVI5KG6P NVvYZ251W0GQR1XS
MHH-ES-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPzRnJiUUN3ME2wMlA2OzFibl2= MYjTRW5ITVJ?
RPMI-7951 MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7BTWM2OD1yLkC1OFEhdk1? MmrNV2FPT0WU
IST-SL2 NFjuTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X2W2lEPTB;MD6wOVg1KG6P MljzV2FPT0WU
CMK MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEW4OkBvVQ>? NX7BelQ3W0GQR1XS
GR-ST NHfWW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L6bmlEPTB;MD6wOVk2KG6P NU[yPWpGW0GQR1XS
NALM-6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DUSGlEPTB;MD6wOlIzKG6P M4jRNnNCVkeHUh?=
RPMI-6666 M13lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i1ZWlEPTB;MD6wOlUzKG6P NH\4Oo9USU6JRWK=
LC-2-ad M4TteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD1yLkC2OVMhdk1? M1HCVHNCVkeHUh?=
ARH-77 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3vTWM2OD1yLkC3NVEhdk1? MnvCV2FPT0WU
IST-MEL1 M3H6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELXfFlKSzVyPUCuNFczPiCwTR?= NYTSTGtjW0GQR1XS
SW1710 M2[yeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrlTXhiUUN3ME2wMlA4PTFibl2= M3PoXnNCVkeHUh?=
DEL M{H6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ae2RKSzVyPUCuNFg5PyCwTR?= MmXlV2FPT0WU
AGS Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPnSIUyUUN3ME2wMlA6ODJibl2= MXTTRW5ITVJ?
NCI-H2122 NFTNS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEm0OkBvVQ>? NVL3cVJEW0GQR1XS
HSC-4 M4DTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYSFlQUUN3ME2wMlExOiCwTR?= MkHKV2FPT0WU
AM-38 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUKxJI5O Mn61V2FPT0WU
769-P M{HpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDMUWM5UUN3ME2wMlEzOyCwTR?= NY\xRlZJW0GQR1XS
RT-112 NEnafXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMUK3JI5O MlTCV2FPT0WU
MCF7 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofjTWM2OD1yLkGzOkBvVQ>? NFrxO4xUSU6JRWK=
IGROV-1 NH62S3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLtPIgzUUN3ME2wMlE1PSCwTR?= Mlr1V2FPT0WU
OCI-AML2 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT4bpo6UUN3ME2wMlE1PyCwTR?= NILQXpVUSU6JRWK=
NCI-H1299 NWTuT|M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTZSpJIUUN3ME2wMlE2PyCwTR?= MYHTRW5ITVJ?
A431 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTLeZBKSzVyPUCuNVg{KG6P MXPTRW5ITVJ?
SW982 NXTMV2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjxTWM2OD1yLkKxN{BvVQ>? MX;TRW5ITVJ?
BB30-HNC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1yLkKzNUBvVQ>? MWnTRW5ITVJ?
ACN NVLLVYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\F[21RUUN3ME2wMlI1PCCwTR?= NF\FXYxUSU6JRWK=
647-V NWG5XHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPVTWM2OD1yLkK0PEBvVQ>? M1SyPHNCVkeHUh?=
SK-PN-DW MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMk[2JI5O M33u[nNCVkeHUh?=
LCLC-97TM1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPnUpY5UUN3ME2wMlI3PyCwTR?= MV7TRW5ITVJ?
LB1047-RCC MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMk[5JI5O MYDTRW5ITVJ?
A2780 M37CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\uR|VCUUN3ME2wMlI4KG6P Mmf2V2FPT0WU
C-33-A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfxVJF6UUN3ME2wMlI4OyCwTR?= NIKxenVUSU6JRWK=
NCI-H2228 NIXvdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjvTWM2OD1yLkOxOEBvVQ>? MWfTRW5ITVJ?
TE-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHoS4xKSzVyPUCuN|E3KG6P MlfJV2FPT0WU
HC-1 NVHBUHRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXMfYh{UUN3ME2wMlMzPyCwTR?= MofaV2FPT0WU
SK-MES-1 NW\hbmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwM{K4JI5O NYnK[nJqW0GQR1XS
NCI-H1355 NHXZdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL5TWM2OD1yLkO4NUBvVQ>? M2LxZnNCVkeHUh?=
YKG-1 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ns[mlEPTB;MD60NVkhdk1? MX\TRW5ITVJ?
RS4-11 M17Yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\JT5JKSzVyPUCuOFM{KG6P M1TYRnNCVkeHUh?=
Daoy NIr0VoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6SWlEPTB;MD60OVYhdk1? M4DnXnNCVkeHUh?=
A3-KAW M1vQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4TWM2OD1yLkW1NUBvVQ>? M{[0e3NCVkeHUh?=
SK-MEL-30 NULr[GtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;CTWJKSzVyPUCuOVU1KG6P MnzzV2FPT0WU
U031 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrUVG9KSzVyPUCuOVY2KG6P NGThWotUSU6JRWK=
SK-LMS-1 NILxVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXkTWM2OD1yLkW3PEBvVQ>? NHfENIZUSU6JRWK=
ES6 M{D5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITHXFVKSzVyPUCuOVg3KG6P MUXTRW5ITVJ?
EoL-1-cell M2rkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnTS3JiUUN3ME2wMlYyPiCwTR?= M4rNRXNCVkeHUh?=
NCI-H2009 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwNkG5JI5O MV;TRW5ITVJ?
A4-Fuk NXzQO2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHoNWU4UUN3ME2wMlYzPiCwTR?= MYjTRW5ITVJ?
KYSE-270 NIe4XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPIc5FYUUN3ME2wMlY{PCCwTR?= MoLIV2FPT0WU
SK-LU-1 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNkW1JI5O MYjTRW5ITVJ?
SW872 NFnmeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofqTWM2OD1yLke2OUBvVQ>? M2PGVXNCVkeHUh?=
ES8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HlO2lEPTB;MD63PEBvVQ>? M2rGVXNCVkeHUh?=
G-402 M2rldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwN{i0JI5O NUPpWmFEW0GQR1XS
ATN-1 M4PD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7UTWM2OD1yLkiwO{BvVQ>? M3[4SHNCVkeHUh?=
DoTc2-4510 NI\NcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwOUCxJI5O MX7TRW5ITVJ?
MES-SA NVmzPWlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwOUC1JI5O MVXTRW5ITVJ?
SF268 NFnRU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwOUK3JI5O NIH0b49USU6JRWK=
SF539 NFrKT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwMEKgcm0> MYLTRW5ITVJ?
NB69 M12xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XOPGlEPTB;MT6wOUBvVQ>? MVvTRW5ITVJ?
8505C NV\6Uot1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\6bmFKSzVyPUGuNFYhdk1? MnLhV2FPT0WU
CAL-12T NYrDVmw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGeVJKSzVyPUGuNFghdk1? M2TRPHNCVkeHUh?=
BHY MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK5VZY2UUN3ME2xMlE1KG6P MVjTRW5ITVJ?
LB647-SCLC MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13UO2lEPTB;MT6xPEBvVQ>? NHTUe2hUSU6JRWK=
CAL-62 NYWzcI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TvS2lEPTB;MT6yNkBvVQ>? NXrFPXg5W0GQR1XS
MEG-01 NVXSfnplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PSO2lEPTB;MT6yO{BvVQ>? MYjTRW5ITVJ?
MG-63 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33qV2lEPTB;MT6zN{BvVQ>? MVnTRW5ITVJ?
SW620 M3zlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XWbWlEPTB;MT6zOUBvVQ>? NV7RV|JbW0GQR1XS
A388 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGew[|VKSzVyPUGuN|Yhdk1? NF7TfIZUSU6JRWK=
BCPAP M1fuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z5fmlEPTB;MT60OUBvVQ>? Mn3FV2FPT0WU
P30-OHK MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;IN3VuUUN3ME2xMlQ3KG6P NWrJRYpKW0GQR1XS
Ca9-22 NX3CZY5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTWeZRKSzVyPUGuOVQhdk1? MXjTRW5ITVJ?
VMRC-RCZ NFzKdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fWV2lEPTB;MT61OEBvVQ>? NIrvTmFUSU6JRWK=
LOXIMVI MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXtWVhKSzVyPUGuOkBvVQ>? MknDV2FPT0WU
L-540 M4W1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjVTWM2OD1zLk[gcm0> NELpNIxUSU6JRWK=
NTERA-S-cl-D1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHJVYxKSzVyPUGuOlQhdk1? M4K3XHNCVkeHUh?=
MFH-ino NFjXVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvjTWM2OD1zLk[2JI5O Mn7yV2FPT0WU
Calu-6 M1TTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz4TWM2OD1zLkezJI5O NIX5UYlUSU6JRWK=
HEL Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j5ZWlEPTB;MT63PUBvVQ>? NXHVZW5UW0GQR1XS
CAL-33 NE\pWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HqV2lEPTB;MT64PUBvVQ>? M164UnNCVkeHUh?=
HSC-3 M2n2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlztTWM2OD1zLkmxJI5O M{GxTXNCVkeHUh?=
KU812 NW\vO5EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\oWWlEPTB;MT65NUBvVQ>? MkfOV2FPT0WU
EB2 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLqR214UUN3ME2yMlAyKG6P M4T0U3NCVkeHUh?=
SR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwMUKgcm0> NWD4XlBFW0GQR1XS
NCI-H2087 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnUdG0{UUN3ME2yMlE1KG6P Mn[zV2FPT0WU
H4 NFnKUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOze24yUUN3ME2yMlE5KG6P MVPTRW5ITVJ?
EW-1 NUH2S4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjBTG5UUUN3ME2yMlIzKG6P NIjUTIFUSU6JRWK=
MC-IXC M{C0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XFUGlEPTB;Mj6yOkBvVQ>? M1G1SXNCVkeHUh?=
NCI-H727 NIPYR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli0TWM2OD1{LkWxJI5O NVfWRXBJW0GQR1XS
MRK-nu-1 M1n0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPzblFKSzVyPUKuOVchdk1? MlLGV2FPT0WU
COLO-668 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wdGlEPTB;Mj62OkBvVQ>? NY[2[IM{W0GQR1XS
CGTH-W-1 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwN{Kgcm0> MWjTRW5ITVJ?
CHP-212 M{fqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJwN{Wgcm0> MY\TRW5ITVJ?
GI-1 M37vd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnixTWM2OD1{Lke2JI5O NUjWPYdFW0GQR1XS
HCC1806 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1{LkmxJI5O NVvRXFBuW0GQR1XS
HLE MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNibl2= Mo[wV2FPT0WU
HSC-2 NFjiWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L6cGlEPTB;Mz6wN{BvVQ>? NU\pN|huW0GQR1XS
DMS-273 M3vlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzHdlBKSzVyPUOuNFchdk1? NEfJSXdUSU6JRWK=
DU-4475 M362TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW4TWM2OD1|LkG0JI5O MVHTRW5ITVJ?
LXF-289 NILoVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H5dmlEPTB;Mz6zNUBvVQ>? NIK4[YtUSU6JRWK=
PANC-03-27 NFTXZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PkeWlEPTB;Mz61NUBvVQ>? NYPYW41DW0GQR1XS
GAMG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwN{Sgcm0> MWDTRW5ITVJ?
NCI-H522 NYm1W3FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTRwM{Sgcm0> MXXTRW5ITVJ?
SW626 M{HsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfNTWM2OD12LkS2JI5O Mo\YV2FPT0WU
HT-144 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZ[pdNUUN3ME20MlkzKG6P M1y4UXNCVkeHUh?=
MEL-HO MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm0TXlqUUN3ME21MlE3KG6P MWXTRW5ITVJ?
BE-13 NGnETHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDoV3FKSzVyPUWuNlEhdk1? NETPdYtUSU6JRWK=
VA-ES-BJ NHzTbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHve5pKSzVyPUWuNlYhdk1? NWTU[|FkW0GQR1XS
NCI-H441 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rqVmlEPTB;NT62JI5O NVfXVII{W0GQR1XS
KP-4 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HWdmlEPTB;NT62NUBvVQ>? MYLTRW5ITVJ?
LoVo NGj0cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXZfllKSzVyPUWuO|Ehdk1? M4DseHNCVkeHUh?=
HT-1080 NWXUSm84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfBSHRKSzVyPUWuPFMhdk1? MmL5V2FPT0WU
GB-1 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3dGpKSzVyPUWuPFQhdk1? NVy4b3BLW0GQR1XS
IA-LM NXmyWmtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXETWM2OD13LkmxJI5O MnvlV2FPT0WU
8-MG-BA NVT3XohNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTVwOUOgcm0> NXH3eVdQW0GQR1XS
SK-HEP-1 NG\vcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n0eWlEPTB;Nj6xOEBvVQ>? MmHmV2FPT0WU
697 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLlTWM2OD14LkK1JI5O MUXTRW5ITVJ?
KYSE-450 NGfCZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ZZW9GUUN3ME22MlMzKG6P MWTTRW5ITVJ?
HCC2998 NGXZ[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwM{Sgcm0> NYriT3duW0GQR1XS
HD-MY-Z MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDJTWM2OD14Lk[4JI5O NWfDWnh6W0GQR1XS
OS-RC-2 M3u0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD14Lk[4JI5O NWm5UmZmW0GQR1XS
SF126 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLBepFKSzVyPUeuNFUhdk1? MnnXV2FPT0WU
Ca-Ski NFX1XlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPmTWM2OD15LkC5JI5O NWTjV4JZW0GQR1XS
NCI-H358 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rWZWlEPTB;Nz6xOkBvVQ>? MkLNV2FPT0WU
J82 M{P2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zj[GlEPTB;Nz60NUBvVQ>? M1\yTHNCVkeHUh?=
NCI-H2342 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\vTWM2OD15Lk[zJI5O MYTTRW5ITVJ?
OVCAR-8 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjEVpZKSzVyPUeuPUBvVQ>? NWLTO3RzW0GQR1XS
TE-8 NEjKRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX4TWM2OD16IH7N MYHTRW5ITVJ?
ETK-1 NUPIOnZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjucY5KSzVyPUiuNFghdk1? MVTTRW5ITVJ?
HAL-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ObmlEPTB;OD6yJI5O MlXwV2FPT0WU
KYSE-150 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFexXopKSzVyPUiuOFchdk1? MWHTRW5ITVJ?
NCI-H810 NV;xOIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRThwNU[gcm0> NH7Nc4hUSU6JRWK=
ONS-76 NWHBXVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3jUFB[UUN3ME24MlY5KG6P Mnz6V2FPT0WU
NMC-G1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSzXpgyUUN3ME24Mlc3KG6P Mm\0V2FPT0WU
C3A Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPMWpB5UUN3ME24Mlg1KG6P M1rGTHNCVkeHUh?=
PA-1 NIfI[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3OlZKSzVyPUiuPVkhdk1? NG\yPZBUSU6JRWK=
SH-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfHeWptUUN3ME25MlAzKG6P M{LzenNCVkeHUh?=
EFO-27 NIjBZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wV4FjUUN3ME25MlA2KG6P NF\J[5RUSU6JRWK=
CAPAN-1 M4myb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPXTWM2OD17LkKzJI5O NHfCS5RUSU6JRWK=
DU-145 NYrBTFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\3ZY5KSzVyPUmuNlkhdk1? M4K5[nNCVkeHUh?=
A101D M3TFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly2TWM2OD17LkO3JI5O MnzWV2FPT0WU
ST486 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\2TWM2OD17LkSxJI5O M1XNcHNCVkeHUh?=
NCI-H1437 M{j1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK3eVBmUUN3ME25MlQzKG6P M4TvZXNCVkeHUh?=
HGC-27 NFHJOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;YO2lEPTB;OT62JI5O M2DhbHNCVkeHUh?=
8305C NEnYNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLLR5NKSzVyPUmuOlQhdk1? M1rXR3NCVkeHUh?=
OCUB-M NVrVcmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnnR4lKSzVyPUGwMlA{KG6P NVLURlN1W0GQR1XS
COLO-679 M1\w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKx[XpbUUN3ME2xNE4xPyCwTR?= MX;TRW5ITVJ?
Detroit562 M4rFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;vS|E5UUN3ME2xNE41OiCwTR?= NUjIbXozW0GQR1XS
A204 M17seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLTTWM2OD1zMT6xOkBvVQ>? NVrVVIRxW0GQR1XS
NCI-H1734 NV\sNWg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFzLkK5JI5O MnHjV2FPT0WU
MC-CAR Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGy[JhKSzVyPUGxMlU5KG6P M{PyN3NCVkeHUh?=
NCI-H2170 NVfOWoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFzLkm3JI5O NH\N[FNUSU6JRWK=
NCI-SNU-5 M{LJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF{LkGzJI5O MlnpV2FPT0WU
HCE-T M3v2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPrTWM2OD1zMj60NkBvVQ>? MkPuV2FPT0WU
KYSE-180 M2jMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILySY1KSzVyPUGyMlgyKG6P NFjkPYZUSU6JRWK=
C8166 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF|LkC4JI5O Ml31V2FPT0WU
NCI-H460 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknYTWM2OD1zMz61OEBvVQ>? M4TS[3NCVkeHUh?=
SNU-449 NW\HTnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofNTWM2OD1zMz63O{BvVQ>? MoPJV2FPT0WU
MDA-MB-468 NI\UXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC3XJppUUN3ME2xOE4yOiCwTR?= MVHTRW5ITVJ?
COR-L23 MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjKfIpOUUN3ME2xOE4yOyCwTR?= M3XLPHNCVkeHUh?=
CTV-1 NVn3bWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LFRWlEPTB;MUSuNVQhdk1? NInTb4RUSU6JRWK=
BL-41 M3nDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD1zND6zO{BvVQ>? NXT2SHJLW0GQR1XS
IGR-1 NV;xXVNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3NVFKSzVyPUG0MlQzKG6P M3PxdnNCVkeHUh?=
TK10 NEnZU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoS2lEPTB;MUSuOFkhdk1? MoX1V2FPT0WU
REH MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jaUmlEPTB;MUSuOVEhdk1? NFHvUoRUSU6JRWK=
LU-139 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBUWtKSzVyPUG0MlU6KG6P MoW1V2FPT0WU
KP-N-YS M17tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF2Lkm3JI5O MUXTRW5ITVJ?
PANC-10-05 NXO3NVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33V[WlEPTB;MUWuN|ghdk1? Ml7JV2FPT0WU
HL-60 NFj4fYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF3Lk[5JI5O NY\we|lXW0GQR1XS
T84 NF\X[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\Ke|dKSzVyPUG1Mlk3KG6P NV\reVVXW0GQR1XS
RPMI-8226 NX;LS2N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1WIJZUUN3ME2xOk4xOiCwTR?= MYPTRW5ITVJ?
UM-UC-3 M{CwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPzcZBKSzVyPUG2MlE3KG6P NUDieolKW0GQR1XS
TE-10 M1njNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqfIVwUUN3ME2xOk4zOSCwTR?= M1qyOHNCVkeHUh?=
CAL-148 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnaTWM2OD1zNz6yN{BvVQ>? NGi2V2pUSU6JRWK=
BV-173 NFfEUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC3[nRJUUN3ME2xO{4zPyCwTR?= MkfaV2FPT0WU
Calu-3 NYjKPItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7kd4Z2UUN3ME2xO{4zQSCwTR?= M4rPZnNCVkeHUh?=
RPMI-2650 NI\ZSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jzOWlEPTB;MUeuOVkhdk1? NIDL[lNUSU6JRWK=
MKN45 NYThOZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW3UJRQUUN3ME2xO{44OyCwTR?= NET3[lVUSU6JRWK=
NUGC-3 NX35[m95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mxUWlEPTB;MUiuN|Qhdk1? NUKze4VrW0GQR1XS
NCI-H520 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF6Lke3JI5O NGTBVWZUSU6JRWK=
CCRF-CEM NFXtNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1roeGlEPTB;MUiuPFUhdk1? MX\TRW5ITVJ?
NCI-H2405 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITGbmFKSzVyPUG5MlEhdk1? M2TvTnNCVkeHUh?=
ES7 NFjqc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn70TWM2OD1zOT63OkBvVQ>? MX3TRW5ITVJ?
BPH-1 NVrU[HpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJyLkK4JI5O NU\nVld5W0GQR1XS
SAS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u1eGlEPTB;MkCuOUBvVQ>? M3zGdXNCVkeHUh?=
HuCCT1 M3XNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJyLkW4JI5O NVTIPHpCW0GQR1XS
LOUCY NIDaXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJyLk[2JI5O MkLXV2FPT0WU
NCI-H292 NV7FcWprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJyLke5JI5O NV\vPFQ{W0GQR1XS
G-361 NYnCOGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD1{MT6wO{BvVQ>? NWn4fFlpW0GQR1XS
M059J MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq5Wm5oUUN3ME2yNU4xQCCwTR?= MlLaV2FPT0WU
NCI-H1651 NYm4UmFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXywfGdpUUN3ME2yNU4yOSCwTR?= NVTDR2tyW0GQR1XS
KALS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjY[GxKSzVyPUKxMlM6KG6P NFzKTFNUSU6JRWK=
DJM-1 NW\YXoFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7CTWM2OD1{MT61PUBvVQ>? MWrTRW5ITVJ?
AU565 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJzLkizJI5O NWPFVZJLW0GQR1XS
HCC38 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jlPWlEPTB;MkGuPVUhdk1? NXyxcmhkW0GQR1XS
U251 NFO2R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ{LkK3JI5O MWXTRW5ITVJ?
ABC-1 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7meFZKSzVyPUKyMlY2KG6P NYWwZW03W0GQR1XS
SK-NEP-1 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rQNGlEPTB;MkKuPVMhdk1? NELs[VZUSU6JRWK=
CESS NHHa[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTSFlKSzVyPUKzMlE6KG6P MnzkV2FPT0WU
MIA-PaCa-2 M4LJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\TXW1KSzVyPUKzMlM3KG6P M3PsdXNCVkeHUh?=
SUP-T1 NVrZUYZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fTNmlEPTB;MkOuOFchdk1? MnLsV2FPT0WU
L-428 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTBVmFKSzVyPUKzMlYzKG6P MYDTRW5ITVJ?
SW954 NIDFSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ|Lk[4JI5O MWrTRW5ITVJ?
HO-1-N-1 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;XU2lEPTB;MkOuO|chdk1? NXH2[otqW0GQR1XS
CHP-126 NFnhTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ2LkG0JI5O M3\Cd3NCVkeHUh?=
HMV-II NIPYdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17Zb2lEPTB;MkSuN|Qhdk1? MmLqV2FPT0WU
NB10 M{nBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ2LkO3JI5O M{S0dHNCVkeHUh?=
A172 NYDISlNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUS2lEPTB;MkSuO|Ehdk1? MWrTRW5ITVJ?
MONO-MAC-6 NH3ZbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILFVolKSzVyPUK0Mlg1KG6P MlHXV2FPT0WU
NCI-H1650 M{G1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJ3LkSgcm0> NX\TeJlbW0GQR1XS
NH-12 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDmR5RKSzVyPUK1MlUhdk1? NH3rSpZUSU6JRWK=
ML-2 NWrXXJppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LTb2lEPTB;MkWuO|Qhdk1? MmXHV2FPT0WU
MZ2-MEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ4LkKyJI5O M{jQV3NCVkeHUh?=
COLO-684 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ4LkSxJI5O NWf1ZXQ5W0GQR1XS
HuP-T4 M{XUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHwbGJzUUN3ME2yO{4{KG6P NG\rdHhUSU6JRWK=
SW837 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ5Lk[yJI5O MYjTRW5ITVJ?
MDA-MB-231 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\TcGFKSzVyPUK3Mlc5KG6P NGXSenNUSU6JRWK=
KYSE-140 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ5LkmxJI5O NUnXfmY{W0GQR1XS
NOMO-1 NHPDTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ6Lk[4JI5O M1f0NXNCVkeHUh?=
GP5d MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFToZnpKSzVyPUK4MlczKG6P MVXTRW5ITVJ?
COR-L105 M1XJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnjUJJKSzVyPUK5MlQzKG6P NYK2O|l1W0GQR1XS
LS-411N NGDrXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPET5ROUUN3ME2yPU45QCCwTR?= MmLoV2FPT0WU
NY M3TadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID4eopKSzVyPUOwMlE5KG6P NYfmUFJIW0GQR1XS
NCI-H2030 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTqTWM2OD1|MD60OUBvVQ>? NUC4S3hbW0GQR1XS
CCF-STTG1 M3LSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn4SoxKSzVyPUOxMlQzKG6P NXfEdoZlW0GQR1XS
NCI-H1703 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke1TWM2OD1|MT63PEBvVQ>? MlywV2FPT0WU
TUR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj2TIVjUUN3ME2zNk4xOyCwTR?= M1zOUHNCVkeHUh?=
NOS-1 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn5cYxKSzVyPUOyMlQ1KG6P NV73cI9DW0GQR1XS
A2058 NGfRNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LEPGlEPTB;M{KuPFMhdk1? MUnTRW5ITVJ?
LCLC-103H NXTlbZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN|LkK1JI5O M2PKe3NCVkeHUh?=
NCI-H510A MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jUbWlEPTB;M{OuNlchdk1? M4rLT3NCVkeHUh?=
BC-1 NEjuO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN|Lke3JI5O Mo\MV2FPT0WU
SK-CO-1 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2OI9KSzVyPUO0MlAyKG6P M3TSZXNCVkeHUh?=
A673 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN2LkG3JI5O NUew[|g2W0GQR1XS
VM-CUB-1 NVfiS3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN2Lk[5JI5O NFPGXWpUSU6JRWK=
HH MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u0[GlEPTB;M{WuNFYhdk1? MlvHV2FPT0WU
CAL-27 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXYWpZZUUN3ME2zOU4yPiCwTR?= NIr2WnVUSU6JRWK=
NEC8 M1XMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN3LkO3JI5O MUnTRW5ITVJ?
BxPC-3 M4HDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN4LkmxJI5O NGPVfmdUSU6JRWK=
SNB75 NHrZV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nqfmlEPTB;M{euNlQhdk1? MYrTRW5ITVJ?
NB13 NWfse3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TMTGlEPTB;M{iuNlMhdk1? NXX3PJpDW0GQR1XS
SK-OV-3 M3rkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17rO2lEPTB;M{iuO|Qhdk1? NXXV[3ZbW0GQR1XS
ME-180 NID0cXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLrcpBFUUN3ME2zPE45KG6P MmfFV2FPT0WU
JiyoyeP-2003 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32TWM2OD1|OT6zPEBvVQ>? MmnDV2FPT0WU
LU-134-A MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzpTolKSzVyPUSwMlAzKG6P M{H0cnNCVkeHUh?=
LS-123 NGL4bIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\0fnRKSzVyPUSwMlI5KG6P MmfXV2FPT0WU
COLO-800 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jlZmlEPTB;NECuOVYhdk1? MY\TRW5ITVJ?
LB831-BLC NFTRVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vFZ2lEPTB;NEGuPFUhdk1? NHuzVoZUSU6JRWK=
NCI-H747 M2XieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR{LkK4JI5O MVTTRW5ITVJ?
MZ7-mel MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLmZYhjUUN3ME20Nk43PiCwTR?= NHnpeINUSU6JRWK=
GT3TKB NXi1TZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX1[lFKSzVyPUSyMlczKG6P M1zReXNCVkeHUh?=
MOLT-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPB[oNKSzVyPUSzMlA2KG6P MV;TRW5ITVJ?
23132-87 NVrFZXRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnniTWM2OD12Mz6wOUBvVQ>? M1zUSnNCVkeHUh?=
PF-382 NHrnZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq5TWM2OD12ND6yNkBvVQ>? Mn\1V2FPT0WU
ES3 M1vuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzwUW9KSzVyPUS0MlYhdk1? MmnQV2FPT0WU
SW756 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\oTWM2OD12NT6xOEBvVQ>? MXnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 在胰腺L3.6pl肿瘤转移的裸鼠中,Gemcitabine和C225联用导致生长抑制,肿瘤消退。Gemcitabine单独给药治疗减少了平均肿瘤体积,从538到152毫米。在Gemcitabine治疗的肿瘤中,Gemcitabine可以减少血管内皮生长因子和白细胞介素8的产生。[2] Gemcitabine是能够显著地和特异地减少骨髓抑制性细胞的数量,并不显著改变CD4(+)T细胞,CD8(+)T细胞,NK细胞,巨噬细胞,或B细胞的数量。[4] Gemcitabine和curcumin联用显著减少肿瘤体积(与对照组和单独Gemcitabine处理相比),Ki-67的增殖指数(与对照组相比),NF-κB的激活和表达NF-κB的调节基因产物(细胞周期蛋白D1,c-myc的和Bcl-2和Bcl-xL的细胞凋亡蛋白-1,环氧化酶-2,基质金属蛋白酶,和血管内皮生长因子的细胞抑制剂)。Gemcitabine和curcumin联用也抑制血管生成,以CD31(+)的微血管密度为标志。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water (warmed)
52mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 263.2
化学式

C9H11F2N3O4

CAS号 95058-81-4
稳定性 powder
in solvent
别名 LY-188011, NSC 613327

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03085004 Not yet recruiting Pancreatic Cyst|EUS-FNA Milton S. Hershey Medical Center January 2019 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Gemcitabine | Gemcitabine ic50 | Gemcitabine 价格 | Gemcitabine DMSO溶解度 | 采购Gemcitabine | Gemcitabine 生产 | Gemcitabine 小鼠 | Gemcitabine 化学结构 | Gemcitabine 分子量 | Gemcitabine molecular weight | Gemcitabine 说明书 | Gemcitabine 供应商 | Gemcitabine 体内 | Gemcitabine 细胞系 | Gemcitabine 浓度 | Gemcitabine nmr | Gemcitabine 核磁 | Gemcitabine 半数抑制浓度 | Gemcitabine 体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID